Back to User profile » Dr Tohru Inaba
Papers published by Dr Tohru Inaba:
Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant Recipient [Corrigendum]
Tanino Y, Nishioka K, Yamamoto C, Watanabe Y, Daidoji T, Kawamoto M, Uda S, Kirito S, Nakagawa Y, Kasamatsu Y, Kawahara Y, Sakai Y, Nobori S, Inaba T, Ota B, Fujita N, Hoshino A, Nukui Y, Nakaya T
Infection and Drug Resistance 2024, 17:951-952
Published Date: 11 March 2024
Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant Recipient
Tanino Y, Nishioka K, Yamamoto C, Watanabe Y, Daidoji T, Kawamoto M, Uda S, Kirito S, Nakagawa Y, Kasamatsu Y, Kawahara Y, Sakai Y, Nobori S, Inaba T, Ota B, Fujita N, Hoshino A, Nukui Y, Nakaya T
Infection and Drug Resistance 2024, 17:531-541
Published Date: 8 February 2024
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms
Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, Nishiyama D, Shimura K, Kaneko H, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J
Infection and Drug Resistance 2023, 16:509-519
Published Date: 25 January 2023
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical Implication of the Effect of the Production of Neutralizing Antibodies Against SARS-Cov-2 for Chronic Immune Thrombocytopenia Flare-Up Associated with COVID-19 Infection: A Case Report and the Review of Literature
Maekura C, Muramatsu A, Nagata H, Okamoto H, Onishi A, Kato D, Isa R, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Okumura K, Inaba T, Nukui Y, Kuroda J
Infection and Drug Resistance 2022, 15:2723-2728
Published Date: 31 May 2022
![Noteworthy comment: Cyclical Hypereosinophilia, or Gleichs syndrome, a variant of the broader category of Hypereosinophilia Syndrome, may encompass yet other variants as is the situation described in the current case report by Imashuku et al. The time between cycles for the case described had a periodicity longer than those reported previously: three times per year and was FIILI-PDGFRA fusion gene negative. This new variant showed only partial response to treatment with imatinib mesylate (a treatment generally effective in other variants of this syndrome) but did respond to a triad of cyclosporine A, suplatast tosilate and a small dose of prednisolone, over a recent 6 year period. This is a new variant of a rare syndrome not previously described and is indeed noteworthy.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Effectiveness of a combination of cyclosporine A, suplatast tosilate and prednisolone on periodic oscillating hypereosinophilia
Imashuku S, Ueda I, Inaba T
International Medical Case Reports Journal 2011, 4:79-82
Published Date: 8 November 2011